{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:23:37Z","timestamp":1792103017907,"version":"4.4.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00259-025-07541-3","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T02:48:07Z","timestamp":1757040487000},"page":"1559-1569","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Effect of bone marrow disease on hematologic toxicity and response to [177Lu]Lu-PSMA-617 therapy: insights from PSMA-PET\/CT imaging"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4846-9110","authenticated-orcid":false,"given":"Nuno","family":"Borges","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meryam","family":"Losee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mofei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Chun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arda","family":"K\u00f6nik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolivette","family":"Ritzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Wolanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S.C.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atish D.","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary-Ellen","family":"Taplin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praful","family":"Ravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Jacene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,5]]},"reference":[{"issue":"5","key":"7541_CR1","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1053\/hp.2000.6698","volume":"31","author":"L Bubendorf","year":"2000","unstructured":"Bubendorf L, Schopfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000;31(5):578\u201383. https:\/\/doi.org\/10.1053\/hp.2000.6698.","journal-title":"Hum Pathol"},{"issue":"1","key":"7541_CR2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.clgc.2016.07.027","volume":"15","author":"NJ Vogelzang","year":"2017","unstructured":"Vogelzang NJ, Coleman RE, Michalski JM, et al. Hematologic safety of radium-223 dichloride: baseline prognostic factors associated with myelosuppression in the ALSYMPCA trial. Clin Genitourin Cancer. 2017;15(1):42\u2013e528. https:\/\/doi.org\/10.1016\/j.clgc.2016.07.027.","journal-title":"Clin Genitourin Cancer"},{"issue":"12","key":"7541_CR3","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"issue":"5","key":"7541_CR4","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1470-2045(23)00158-4","volume":"24","author":"K Fizazi","year":"2023","unstructured":"Fizazi K, Herrmann K, Krause BJ, et al. Health-related quality of life and pain outcomes with [(177)Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24(5):597\u2013610. https:\/\/doi.org\/10.1016\/S1470-2045(23)00158-4.","journal-title":"Lancet Oncol"},{"issue":"1","key":"7541_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-021-00805-7","volume":"11","author":"D Groener","year":"2021","unstructured":"Groener D, Nguyen CT, Baumgarten J, et al. Hematologic safety of (177)Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer. EJNMMI Res. 2021;11(1): 61. https:\/\/doi.org\/10.1186\/s13550-021-00805-7.","journal-title":"EJNMMI Res"},{"issue":"10","key":"7541_CR6","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","volume":"23","author":"JP Buteau","year":"2022","unstructured":"Buteau JP, Martin AJ, Emmett L, et al. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [(177)Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. Lancet Oncol. 2022;23(10):1389\u201397. https:\/\/doi.org\/10.1016\/S1470-2045(22)00605-2.","journal-title":"Lancet Oncol"},{"issue":"10","key":"7541_CR7","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1007\/s00259-020-04723-z","volume":"47","author":"J Ferdinandus","year":"2020","unstructured":"Ferdinandus J, Violet J, Sandhu S, et al. Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617. Eur J Nucl Med Mol Imaging. 2020;47(10):2322\u20137. https:\/\/doi.org\/10.1007\/s00259-020-04723-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"7541_CR8","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.233460","volume":"312","author":"PH Kuo","year":"2024","unstructured":"Kuo PH, Morris MJ, Hesterman J, et al. Quantitative 68Ga-PSMA-11 PET and clinical outcomes in metastatic castration-resistant prostate cancer following 177Lu-PSMA-617 (VISION Trial). Radiology. 2024;312(2): e233460. https:\/\/doi.org\/10.1148\/radiol.233460.","journal-title":"Radiology"},{"issue":"4","key":"7541_CR9","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2967\/jnumed.118.219352","volume":"60","author":"J Violet","year":"2019","unstructured":"Violet J, Jackson P, Ferdinandus J, et al. Dosimetry of (177)Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes. J Nucl Med. 2019;60(4):517\u201323. https:\/\/doi.org\/10.2967\/jnumed.118.219352.","journal-title":"J Nucl Med"},{"issue":"3","key":"7541_CR10","doi-asserted-by":"publisher","first-page":"252","DOI":"10.2967\/jnmt.123.267002","volume":"52","author":"J Osei-Tutu","year":"2024","unstructured":"Osei-Tutu J, Bennett P, Caravella C, Rini J, Nichols KJ, Palestro CJ. Effect of PSMA PET\/CT on the use of bone scintigraphy for prostate cancer at a university hospital system. J Nucl Med Technol. 2024;52(3):252\u20135. Published 2024 Sep 5.","journal-title":"J Nucl Med Technol"},{"issue":"1","key":"7541_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2967\/jnmt.123.267002","volume":"13","author":"ZJ Wilson","year":"2023","unstructured":"Wilson ZJ, Xu G, Tewari SO, Lu Y. Comparison of PSMA-based 18F-DCFPyL PET\/CT and Tc-99m MDP bone scan in detection of bone metastasis in prostate cancer. Am J Nucl Med Mol Imaging. 2023;13(1):1\u201310. https:\/\/doi.org\/10.2967\/jnmt.123.267002. Published 2023 Feb 15.","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"2","key":"7541_CR12","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2020.05.004","volume":"78","author":"A Gafita","year":"2020","unstructured":"Gafita A, Fendler WP, Hui W, et al. Efficacy and safety of (177)Lu-labeled prostate-specific membrane antigen radionuclide treatment in patients with diffuse bone marrow involvement: a multicenter retrospective study. Eur Urol. 2020;78(2):148\u201354. https:\/\/doi.org\/10.1016\/j.eururo.2020.05.004.","journal-title":"Eur Urol"},{"issue":"11","key":"7541_CR13","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.2967\/jnumed.124.268020","volume":"65","author":"F Pouliot","year":"2024","unstructured":"Pouliot F, Saad F, Rousseau E, et al. Intrapatient intermetastatic heterogeneity determined by triple-tracer PET imaging in mCRPC patients and correlation to survival: the 3TMPO cohort study. J Nucl Med. 2024;65(11):1710\u20137. https:\/\/doi.org\/10.2967\/jnumed.124.268020.","journal-title":"J Nucl Med."},{"key":"7541_CR14","volume-title":"Common terminology criteria for adverse events (CTCAE), version 5.0","author":"U.S. Department of Health and Human Services","year":"2017","unstructured":"U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common terminology criteria for adverse events (CTCAE), version 5.0. Bethesda, MD: National Cancer Institute; 2017."},{"issue":"2","key":"7541_CR15","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jcm.2016.02.012","volume":"15","author":"TK Koo","year":"2016","unstructured":"Koo TK, Li MY. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med. 2016;15(2):155\u201363. https:\/\/doi.org\/10.1016\/j.jcm.2016.02.012.","journal-title":"J Chiropr Med"},{"issue":"3","key":"7541_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030557","volume":"14","author":"J Baumgarten","year":"2022","unstructured":"Baumgarten J, Groener D, Nguyen Ngoc C, et al. Safety and efficacy of 177lutetium-PSMA-617 radioligand therapy shortly after failing 223radium-dichloride. Cancers (Basel). 2022;14(3): 557. https:\/\/doi.org\/10.3390\/cancers14030557.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"7541_CR17","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1007\/s00259-022-05778-w","volume":"49","author":"IO Lawal","year":"2022","unstructured":"Lawal IO, Morgenstern A, Vorster M, et al. Hematologic toxicity profile and efficacy of [225Ac]Ac-PSMA-617 \u03b1-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2022;49(10):3581\u201392. https:\/\/doi.org\/10.1007\/s00259-022-05778-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"7541_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-022-00891-1","volume":"12","author":"F Kind","year":"2022","unstructured":"Kind F, Michalski K, Yousefzadeh-Nowshahr E, Meyer PT, Mix M, Ruf J. Bone marrow impairment during early [177Lu]PSMA-617 radioligand therapy: haematotoxicity or tumour progression? EJNMMI Res. 2022;12(1): 20. https:\/\/doi.org\/10.1186\/s13550-022-00891-1.","journal-title":"EJNMMI Res"},{"issue":"10276","key":"7541_CR19","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, et al. [177Lu]Lu-PSMA-617 versus Cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797\u2013804. https:\/\/doi.org\/10.1016\/S0140-6736(21)00237-3.","journal-title":"Lancet"},{"issue":"11","key":"7541_CR20","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.2967\/jnumed.124.267723","volume":"65","author":"A Gafita","year":"2024","unstructured":"Gafita A, Voter A, Shesadri S, et al. Initial experience with [177Lu]Lu-PSMA-617 after regulatory approval for metastatic castration-resistant prostate cancer: efficacy, safety, and outcome prediction. J Nucl Med. 2024;65(11):1724\u201330. https:\/\/doi.org\/10.2967\/jnumed.124.267723.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07541-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07541-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07541-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T04:43:15Z","timestamp":1769834595000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07541-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7541"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07541-3","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,5]]},"assertion":[{"value":"5 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a retrospective observational study of data obtained from electronic medical record (EMR) review and an institutional review board-approved prospective database that includes all patients who had PSMA-PET\/CT scans and standard-of-care treatment with [177Lu]Lu-PSMA-617 at our institution (DFCI protocol 21\u2013629). The Dana-Farber Harvard Cancer Center IRB waived the requirement for informed written consent. The study was conducted in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Atish D Choudhury: Advisory board: Tolmar, Pfizer, Astellas, Janssen, Sanofi Aventis; Research Funding to Institution: Bayer, Pfizer, Eli Lilly, Sumitomo Pharma; Honoraria for speaking engagement: Bayer, Pfizer, Lantheus.Mary-Ellen Taplin: Advisory board: Blue Earth Diagnostics, Novartis.Thomas Ng: Unrelated support from Lantheus and Bayer; Supported in part by U.S. National Institutes of Health (R21EB036323, R01DK097112), U.S. Department of Defense (W81XWH-22-1-0061), and the Lee Family Foundation.Praful Ravi: Research funding to institution: Lilly, Bayer, Telix, Blue Earth Diagnostics, Lantheus, Novartis; Advisory Board \u2013 Bayer.Heather Jacene: Research Funding to Institution: Blue Earth Diagnostics, Lantheus; Honoraria: Elsevier, intouchCONGRESS, Monrol, ITM; Consulting: Spectrum Dynamics; Royalties: Cambridge Publishing; Stipend: American Journal of Radiology; Supported in part by U.S. National Institutes of Health (R01CA251803, R01Ca235589).All other authors have no disclosures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial interests"}}]}}